We found that the newly formed vessel length in the gastric cancer and tumor growth in the groups that were treated by apatinib at several concentrations could be commonly considerably inhibited in a dose- and time- dependent manner when compared with the control group, which was shown in the previous study to act via inhibiting the AKT/GSK3α/β signaling pathway. The gene discussed is AKT1; the disease is gastric cancer.